-
Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?
Monday, October 7, 2024 - 8:42am | 891Read More...Pfizer Inc. (NYSE:PFE) may have been a hero in the COVID-19 vaccine race, but its stock is stuck in the slow lane. Down nearly 14% over the last year, the pharma giant's shares have struggled as demand for its pandemic-related treatments has fizzled out. But things could get interesting—activist...
-
Pfizer Announces Merger Termination With Allergan; Will Pay $150 Million Breakup Fee
Wednesday, April 6, 2016 - 7:09am | 378Read More...Pfizer Inc. (NYSE: PFE) announced Wednesday morning it has terminated its merger agreement with Allergan plc (NYSE: AGN) following the U.S. Department of Treasury's tax inversion announcement on Monday. Pfizer noted the decision to terminate the merger agreement was mutual. As part of the...
-
Pfizer Reports Better-Than-Expected Q4, Shares Dip Lower
Tuesday, February 2, 2016 - 8:23am | 229Read More...Shares of Pfizer Inc. (NYSE: PFE) were trading lower by around 0.5 percent early Tuesday morning after the company reported its fourth quarter results. Pfizer earned $0.53 per share in the fourth quarter on revenue of $14.05 billion. Wall Street analysts were expecting the company to earn $0.52...
-
Pfizer Buys Allergan In Largest Healthcare Deal Ever
Monday, November 23, 2015 - 10:26am | 733Read More...After months of takeover talks, more consolidation in the healthcare space has come to fruition. On Monday morning, Pfizer Inc. (NYSE: PFE) announced it has purchased Allergan PLC (NYSE: AGN) in a deal valued at about $155 billion, the largest ever in the healthcare sector. The transaction is...
-
These Three Pharma Giants Just Crushed Earnings
Tuesday, October 27, 2015 - 10:09am | 635Read More...Investors have been anxiously awaiting earnings report from pharmaceutical giants to ease ongoing concerns. Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Co (NYSE: BMY), and Merck & Co., Inc. (NYSE: MRK) reported their quarterly Tuesday morning results. Shares of all three names were...
-
Why M&A Doesn't Make Sense For Pfizer Anytime Soon
Thursday, August 13, 2015 - 8:28am | 369Read More...In a report published Wednesday, Bank of America analyst Colin Bristow detailed an investor meeting held with Pfizer Inc. (NYSE: PFE)'s CEO Ian Read and other key senior executives. According to Bristow's meeting, Pfizer noted that one (or several) transformative M&A deal is "...
-
Pfizer Jilted By AstraZeneca; Analyst Sees Break-Up
Tuesday, May 27, 2014 - 2:41pm | 431Read More...The six-month saga of Pfizer's (NYSE: PFE) negotiations with AstraZeneca (NYSE: AZN) came to a crashing halt Monday with the rejection of Pfizer's $117 billion offer. Some analysts are now suggesting a break-up could be in the cards for the U.S. pharmaceuticals giant. Pfizer's "size is its...
-
Pfizer's Heart Races Of AstraZeneca Amidst Rumored Deal & Drug Approval
Thursday, May 8, 2014 - 3:23pm | 937Read More...Pfizer (NYSE: PFE) continues to pursue AstraZeneca plc (NYSE: AZN) despite three rejections this year and grave concern by U.K. politicians. History Of Bids On May 1, 2014, Bloomberg reported that Pfizer could raise its bid for AstraZeneca to more than $106 billion (63 billion pounds) and...
-
Pfizer Conference Call Highlights
Monday, May 5, 2014 - 4:20pm | 1141Read More...Pfizer (NYSE: PFE) on Monday afternoon reported its first quarter earnings. Shares of the company are down 2.7 percent or $0.83 per share to $29.92. Below are some key takeaways from its conference call: Chairman and CEO, Ian Read: • The proposal we announced publicly last Friday represented...
-
Market Wrap For April 28: Apple Hits New 52-Week Highs In a Volatile Start To the Trading Week
Monday, April 28, 2014 - 4:34pm | 2080Read More...U.S. stocks ended the day mostly positive in a volatile trading session as the Nasdaq rebounded from a one percent decline, finishing the day almost flat. The Dow traded higher by as much as 138 points but still ended the day modestly higher as Pfizer's massive $100 billion takeover plans gave...
-
Pfizer Courts AstraZeneca (Again) With $100 Billion Offer
Monday, April 28, 2014 - 10:39am | 628Read More...The “on-again-off-again” courtship of British pharma AstraZeneca (NYSE: AZN) by U.S. drugmaker, Pfizer (NYSE: PFE), was on again, according to a statement from Pfizer. The renewed offer of almost $100 billion may, according to analysts, go over that amount. AstraZeneca rebuffed Pfizer’s $98.9...
-
These Are the 100 Highest-Paid CEOs in Business Today
Monday, April 8, 2013 - 4:30pm | 2706Read More...The New York Times has published a list of the 100 highest-paid CEOS at U.S. public companies in 2012. Oracle (NASDAQ: ORCL) chief executive Larry Ellison is far and away the highest paid CEO on the list, as his $96.2 million in 2012 compensation dwarfs every other member on the list. The top ten...
-
Pfizer CEO Kindler Surprisingly Retires
Sunday, December 5, 2010 - 9:28pm | 133Read More...Pfizer (NYSE: PFE) CEO Jeffrey Kindler has unexpectedly announced his retirement after 4.5 years at the helm of the largest U.S. pharmaceuticals firm. Ian Read will takeover for the 55-year old for Kindler. Kindler oversaw Pfizer's massive $68 billion takeover of Wyeth. Pfizer also reported...
